关键信息
-
基因名
CD46
- 应用
-
别名
CD46；MCP；MIC10；Membrane cofactor Protein
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P15529
-
表达区间
35-328aa
-
氨基酸序列
CEEPPTFEAMELIGKPKPYYEIGERVDYKCKKGYFYIPPLATHTICDRNHTWLPVSDDACYRETCPYIRDPLNGQAVPANGTYEFGYQMHFICNEGYYLIGEEILYCELKGSVAIWSGKPPICEKVLCTPPPKIKNGKHTFSEVEVFEYLDAVTYSCDPAPGPDPFSLIGESTIYCGDNSVWSRAAPECKVVKCRFPVVENGKQISGFGKKFYYKATVMFECDKGFYLDGSDTIVCDSNSTWDPPVPKCLKVLPPSSTKPPALSHSVSTSSTTKSPASSASGPRPTYKPPVSNY
-
分子量
61.6 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
CD46, also known as membrane cofactor protein (MCP), is a pivotal regulator of the complement system and plays a crucial role in immune response modulation. This glycoprotein exists on the surface of various human cells and functions to protect host tissues from complement-mediated lysis by serving as a cofactor for the inactivation of complement component C3b and C4b. Due to its immunoregulatory properties, CD46 has garnered attention in various research fields, including autoimmunity, transplantation, and cancer. Its unique expression patterns in different tissues and cells make it an attractive target for therapeutic applications. Researchers are investigating the potential of CD46 recombinant proteins as novel immunotherapies capable of modulating immune responses, enhancing graft survival in transplantation, and targeting tumor cells. Production of CD46 as a recombinant protein allows for the detailed study of its structure-function relationships and the development of CD46-based biopharmaceuticals. Understanding the molecular mechanisms underlying CD46 interactions and functions could lead to innovative strategies in treating immune-related diseases and improving clinical outcomes in organ transplantation and cancer therapies. Thus, the exploration of CD46 recombinant proteins not only deepens our understanding of the complement system but also opens avenues for novel immunotherapeutic strategies.
